Evercore analyst Vijay Kumar maintains $GE HealthCare Technologies (GEHC.US)$ with a buy rating, and adjusts the target price from $96 to $102.
According to TipRanks data, the analyst has a success rate of 57.6% and a total average return of 5.6% over the past year.
Furthermore, according to the comprehensive report, the opinions of $GE HealthCare Technologies (GEHC.US)$'s main analysts recently are as follows:
In the MedTech sector, continued positive utilization trends are observed going into Q3, and the capital expenditure forecast for the coming year appears favorable. For life science tools, there is an anticipation of improved bioprocess trends in the latter half of the year. Nevertheless, discussions persist regarding the prospects for instruments and the potential impact of China's economic stimulation, especially considering the recent performance of stocks in this segment.
GE Healthcare was the recipient of favorable news when the FDA granted approval for Flurpiridaz, a novel myocardial perfusion imaging (MPI) positron emission tomography (PET) radiopharmaceutical. This product stands out as it is available as a pre-made 'individual dose,' a significant advantage over current on-site dose production methods. According to due diligence with physicians, there is a consensus that Flurpiridaz may offer notable clinical benefits over existing MPI radiopharmaceuticals. Additionally, a swift adoption by current U.S. cardiac PET centers is anticipated, and the availability of Flurpiridaz is expected to substantially widen the scope of U.S. cardiac PET procedures.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
Evercore分析师Vijay Kumar维持$GE HealthCare Technologies (GEHC.US)$买入评级，并将目标价从96美元上调至102美元。
根据TipRanks数据显示，该分析师近一年总胜率为57.6%，总平均回报率为5.6%。
此外，综合报道，$GE HealthCare Technologies (GEHC.US)$近期主要分析师观点如下：
在医疗技术领域，进入第三季度，利用率持续呈现积极趋势，来年的资本支出预测似乎乐观。在生命科学工具方面，预计下半年生物工艺趋势将有所改善。尽管如此，关于工具前景和中国经济刺激的潜在影响的讨论仍在继续，特别是考虑到该细分市场股票的近期表现。
美国食品药品管理局批准了Flurpiridaz，这是一种新型心肌灌注成像（MPI）正电子发射断层扫描（PET）放射性药物，GE Healthcare受到了好消息。该产品之所以脱颖而出，是因为它可以作为预制的 “个人剂量” 提供，与目前的现场剂量生产方法相比，这是一个显著的优势。根据对医生的尽职调查，人们一致认为，与现有的MPI放射性药物相比，Flurpiridaz可能具有显著的临床益处。此外，预计目前的美国心脏pET中心将迅速采用，预计Flurpiridaz的上市将大大扩大美国心脏pET手术的范围。
提示:
TipRanks为独立第三方，提供金融分析师的分析数据，并计算分析师推荐的平均回报率和胜率。提供的信息并非投资建议，仅供参考。本文不对评级数据和报告的完整性与准确性做出认可、声明或保证。
TipRanks提供每位分析师的星级，分析师星级代表分析师所有推荐的过往表现，通过分析师的总胜率和平均回报率综合计算得出，星星越多，则该分析师过往表现越优异，最高为5颗星。
分析师总胜率为近一年分析师的评级成功次数占总评级次数的比率。评级的成功与否，取决于TipRanks的虚拟投资组合是否从该股票中产生正回报。
总平均回报率为基于分析师的初始评级创建虚拟投资组合，并根据评级变化对组合进行调整，在近一年中该投资组合所获得的回报率。
